Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

P. Petrylak, Daniel; M. Tangen, Catherine; Hussain, Maha; N. Lara, Primo; A. Jones, Jeffrey; Ellen Taplin, Mary; A. Burch, Patrick; L. Berry, Donna; M. Moinpour, Carol; Kohli, Manish; C. Benson, Mitchell; J. Small, Eric; Raghavan, Derek; David Crawford, E.

doi:10.1056/nejmoa041318

Public

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Published in New England Journal of Medicine • Oct 6, 2004

Authors:

Daniel P. Petrylak

Catherine M. Tangen

Maha Hussain

Abstract

BACKGROUND: Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer. METHODS: We rando...

Subject

Docetaxel

Estramustine

Mitoxantrone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!